Ipsen closes up to $1.75bn Kartos deal as navtemadlin enters its decisive Phase 3 myelofibrosis test
Ipsen has completed its Kartos Therapeutics acquisition, paying $450 million upfront with up to $1.3 billion in milestones while the 600-patient POIESIS trial tests navtemadlin plus ruxolitinib.
